李德山
性 别： 男 出生年月： 1950-03-30
职 称： 教授 工作单位： 东北农业大学生命科学学院
招生学科1： 生物化学与分子生物学 招生学科2： 无
办公电话： E-mail： deshanli@163.com

 开设研究生课程情况
课程编号 课程名称 课程级别 学时
209302 《生物技术制药》 选修 32
209303 《生物技术制药专业英语》 选修 32
109201 《分子生物学与基因工程Ⅱ》 选修 32
109202 《分子生物学与基因工程Ⅱ实验》 选修 64
《分子免疫学》54
 近五年主持科研项目概况
1. 东北农业大学治疗2型糖尿病新基因药物脂糖素开发项目（省发改委），1000万
2. 猪流行性腹泻、鸡传染性法氏囊和鸭病毒性肝炎Ⅰ型+Ⅲ型重组治疗抗体（CHO细胞源）的研制，160万
3. 万级洁净实验室（中试车间）和配套设备开发项目，200万
4. 高效生产治疗结直肠癌的西妥昔单抗工程细胞株构建、筛选与生产工艺的建立（省攻关），50万
5. 国家自然基金东北农业大学生物学理科基地科研训练及科研能力提高项目，10万
6. 黑龙江省科技成果转化瓶颈的对策研究（省攻关），7万
7. 成纤维细胞生长因子（FGF）-21中试工艺研究（教育厅），10万
8. 脂糖素（FGF-21）中试工艺的研究（哈市科技局），7万



 近五年项目获奖概况
1  任桂萍、李德山、尹杰超、王文飞、李璐，“Fibroblast growth factor (FGF)-21 signals through both FGF receptor-1 and 2” ，哈市科技局，哈尔滨市自然科学技术学术成果奖，二等奖，2011
2  李德山、任桂萍、李璐、王文飞、朱慧萌、吴云舟、高华山、徐黎明、李晋南，“应用抗体工程技术研发治疗类风湿性关节炎创新药物的研究”， 哈市科技局，哈尔滨市自然科学技术进步奖，三等奖，2011
3  任桂萍、李璐、李德山、矫洪涛、孙国鹏、曲栗、于艺雪、高学慧、刘向宇，“用高通量筛选（MACS/FACS）筛选新的医学靶基因的研究”， 哈市科技局，哈尔滨市自然科学技术进步奖，三等奖，2011



 近五年代表性著作、论文
1. Fangming Kan, Guiping Ren, Mo Guo, Jianying Qi, Yu Zhang, Yang Han, Yakun Zhang, Deshan Li. Construction of an anti-IL-1β scfv and TNFRI fusion protein and its therapeutic effect on RA mice model. Current Pharmaceutical Biotechnology, 2013, 14（12）：1048-1061 （Factor：2.69）
2. Ye X, Qi J, Sun G, Ren G, Zhu S, Wu Y, Yu D, Zhao J, Liu M, Li D. Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation. Curr Pharm Biotechnol. 2013;14(15):1287-1298. （Factor：2.69）
3. Shenglong Zhu, Lei Ma, Yunzhou Wu, Xianlong Ye, Tianyuan Zhang, Qingyang Zhang, Lubna Muhi Rasoul,Yunye Liu,Mo Guo, Bing Zhou, Guiping Ren, and Deshan Li. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin. 2014; 46(12):1041-1048.
（Factor：2.089）
4. Xianlong Ye, Jianying Qi, Guiping Ren, Pengfei Xu, Yunzhou Wu, Shenglong Zhu, Dan Yu, Shujie Li, Qiang Wu, Rasool Lubna Muhi, Deshan Li. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice. Endocrine, 2015,49（3）：683–692 ( Impact Factor: 3.527)
5. Yinhang Yu, Siming Li, Yaonan Liu, Guiyou Tian, Qingyan Yuan, Fuliang Bai, Wenfei Wang, Zhiyi Zhang, Guiping Ren, Yu Zhang, Deshan Li. Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. International Immunopharmacology. 2015,25(1):74-82 ( Impact Factor: 2.711)
6. Yinhang Yu, Fuliang Bai, Yaonan Liu, Yongbi Yang, Qingyan Yuan, Dehua Zou, Susu Qu, Guiyou Tian, Liying Song, Tong Zhang, Siming Li, YunYe Liu, Wenfei Wang, Guiping Ren, Deshan Li. Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Mol Cell Biochem. 2015, 403(1-2):287-299 ( Impact Factor: 2.388)
7. Pengfei Xu, Xianlong Ye, Yingjie Zhang, Qingyan Yuan, Mingyao Liu, Qiang Wu, Guiping Ren, Deshan Li. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. Journal of Diabetes and its Complications. 2015,29(1):5-12 （Factor：3.005）
8. Yinhang Yu, Fuliang Bai, Wenfei Wang, Yaonan Liu, Qingyan Yuan, Susu Qu, Tong Zhang, Guiyou Tian, Siming Li, Deshan Li, Guiping Ren. Fibroblast growth factor 21 protects mouse brain against D-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacology, Biochemistry and Behavior, 2015, 133:122-13
( Impact Factor: 2.82)
9. Pengfei Xu, Yingjie Zhang, Wenfei Wang, Qingyan Yuan, Zhihang Liu, Lubna Muhi Rasoul, Qiang Wu, Mingyao Liu, Xianlong Ye, Deshan Li, Guiping Ren. Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice. Digestive Diseases and Sciences, 2015, 60（10）:3032-3043 ( Impact Factor: 2.613)
10. Yin Bai, Yanmin Chen, Nan Zhang, Xiaochen Guo, Jingzhuang Zhao, Fuxiang Wang, Pengfei Xu, Qingyan Yuan, Jianying Qi, Wenfei Wang, Deshan Li and Guiping Ren. Isolation of the neutralization ScFvs against HBV infection from the immunized population. Current Pharmaceutical Biotechnology, 2015, 16(10): 902-910. ( Impact Factor: 1.95)
11. Guiping Ren, Guiyou Tian, Yunye Liu, Jinjiao He, Xinyu Gao, Yinhang Yu, Xin Liu, Xu Zhang, Tian Sun, Shuangqing Liu, Jiechao Yin, and Deshan Li. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy. Technology in Cancer Research & Treatment ( Impact Factor: 1.730)
12. Qi J, Kan F, Ye X, Guo M, Zhang Y, Ren G, Li D. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis. Int Immunopharmacol. (International Immunopharmacology). 2012, 14(4):770-778.
( Impact Factor:2.376)
13. Zhang Y, Ren G, Guo M, Ye X, Zhao J, Xu L, Qi J, Kan F, Liu M, Li D. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol. (International Immunopharmacology.) 2013, 15(2):199-205. ( Impact Factor:2.376)
14. Jianying Qi, Xianlong Ye, Guiping Ren, Fangming Kan, Yu Zhang, Mo Guo, Zhiyi Zhang, Deshan Li. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis. Molecular Immunology. 2013, 57, (2): 59–65 (factor：2.645)
15. Tianhe Li, Liming Xu, Guiping Ren, Chengkai Yin, Bing Zhou, Xianlong Ye, Qingcui Li, Ning Li and Deshan Li. A Neutralization scFv Antibody against IL-1β Isolated from a NIPA-based Bacterial Display Library. Current Pharmaceutical Biotechnology. 2013, 14(6):571-581 (factor：2.69)
16. Zheng Lv, Tian-Yuan Zhang, Jie-Chao Yin, Hui Wang, Tian Sun, Li-Qun Chen, Fu-Liang Bai, Wei Wu, Gui-Ping Ren, De-Shan Li. Enhancement of Anti-tumor Activity of Newcastle Disease Virus by the Synergistic Effect of Cytosine Deaminase. Asian Pacific Journal of Cancer Prevention, 2013;14(12):7489-7496. （Impact Factor: 1.271）
17. Fuliang Bai, Hui Tian, Zeshan Niu, Mingyao Liu, Guiping Ren, Yinhang Yu, Tian Sun, Siming Li, Deshan LI. Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis. International Journal of molecular medicine, 2014, 33（3）: 711-721. （Impact Factor: 1.957）
18. Mo Guo, Li-Ming Xu, Bing Zhou, Jie-Chao Yin, Xian-Long Ye, Gui-Ping Ren, De-Shan Li. Anchored periplasmic expression (APEx)-based bacterial display for rapid and high-throughput screening of B cell epitopes. Biotechnology Letters（Biotechnol Lett）, 2014, 36（3）：609-616 （Impact Factor:1.853）
19. Yunzhou Wu, Shijun Yan, Zheng Lv, Lin Chen, Jingshu Geng, Jinjiao He, Qingzhong Yu, Jiechao Yin, Guiping Ren, Deshan Li. Recombinant Newcastle Disease virus Anhinga Strain (NDV/Anh-EGFP) for Hepatoma Therapy. Technology in Cancer Research and Treatment, 2014, 13 (2): 169-175. （Impact Factor:1.943）
20. Fuliang Bai, Zeshan Niu, Hui Tian, Siming Li, Zheng Lv, Tianyuan Zhang, Guiping Ren, Deshan Li. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunology Letters（Immunol Lett.） 2014，159(1-2):36-46. （Impact Factor:2.337）
21. Zeshan Niu, Fuliang Bai, Tian Sun, Hui Tian, Dan Yu, Jiechao Yin, Siming Li, Tianhe Li, Hongwei Cao, Qingzhong Yu, Yunzhou Wu, Guiping Ren, Deshan Li. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model. Technology in Cancer Research and Treatment, 2014, online, Epub ahead print （Impact Factor:1.943）
22. Qingcui Li, Guiping Ren, Liming Xu, Qiuying Wang, Jianying Qi, Wenfei Wang, Bing Zhou，Xiaohui Han, Cuiyu Sun, Qiang Wu, Yinhang Yu, Zhongyi Peng, Shimin Zheng, Deshan Li. Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol. 2014, 21(1): 119–127 ( Impact Factor:2.376)
23. Wen-Fei Wang, Si-Ming Li, Gui-Ping Ren, Wei Zheng, Yu-Jia Lu, Yin-Hang Yu, Wen-Juan Xu, Tian-He Li, Li-Hong Zhou, Yan Li, De-Shan Li. Recombinant murine fibroblast growth factor 21 ameliorate obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine, 2014 ( Impact Factor: 3.527)
24. Fu-Liang Bai, Yin-Hang Yu, Hui Tian, Gui-Ping Ren, Hui Wang, Bing Zhou, Xiao-Hui Han, Qing-Zhong Yu & De-Shan Li. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biology & Therapy. 2014, 15( 9): 1226-1238 ( Impact Factor:3.63)
25. Xu L, Zhang Y, Wang Q, Zhao J, Liu M, Guo M, Jiang Y, Cao H, Li Q, Ren G, Li D. Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry. Int Immunopharmacol. 2014, 24(2):463-473 ( Impact Factor: 2.711)
26. X. Ye, J. Qi, Y. Wu, D. Yu, P. Xu, S. Li, S. Zhu, Q. Wu, G. Ren, D. Li. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice
. Diabetes & Metabolism. 2015, 41(1):82-90 ( Impact Factor: 2.845)
27. F. L. Bai, H. Tian, Q. Z. Yu, G. P. Ren, and D. S. Li. Expressing Foreign Genes by Newcastle Disease Virus for Cancer Therapy. Molecular Biology. 2015, 49(2):171-178
( Impact Factor: 0.74)
28. Si-ming Li, Wen-fei Wang, Li-hong Zhou, Lei Ma, Ying An, Wen-juan Xu, Tian-he Li, Yin-hang Yu, De-shan Li, Yan Liu. Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum. Endocrine, 2014 , May 17 ( Impact Factor: 3.527)
29. Li-Ming Xu, Tian-He Li, Bing Zhou, Mo Guo, Miao Liu, Jing-Zhuang Zhao, Hong-Wei Cao, De-Shan Li. scFv antibodies against infectious bursal disease virus isolated from a combinatorial antibody library by flow cytometry. Biotechnology Letters. 2014, 36,(5):1029-1035 ( Impact Factor: 1.736)
30. Wen-fei Wang, Lei Ma, Ming-yao Liu, Ting-ting Zhao, Tong Zhang, Yong-bi Yang, Hong-xue Cao, Xiao-hui Han, De-shan Li. A novel function for fibroblast growth factor 21: stimulation of NADPH oxidase-dependent ROS generation. Endocrine. 2015, 49:385-395
( Impact Factor: 3.527)
31. Wenfei Wang, Nan Zhang, Tingting Zhao, Mingyao Liu, Tong Zhang & Deshan Li. Inhibition of Tumor Growth by Polyarginine-Fused Mutant Cytosine Deaminase. Applied Biochemistry and Biotechnology, 2015, 175(3):1633-43 ( Impact Factor: 1.687)
32. Zhenyu Zhang, Wei Zhao, Deshan Li, Jinlong Yang, Laszlo Zsak and Qingzhong Yu. Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism. Journal of General Virology, 2015, 96, 2028–2035 ( Impact Factor: 3.183)
33. Pengfei Xu, Yingjie Zhang, Yunye Liu, Qingyan Yuan, Liying Song, Mingyao Liu, Zhihang Liu, Yongbi Yang, Junyan Li, Deshan Li, Guiping Ren. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicology and Applied Pharmacology, 290 (2016) 43-53 (Impact Factor: 3.705)
34. Dan Yu, Xianlong Ye, Qiang Wu, Shujie Li, Yongbi Yang, Jinjiao He, Yunye Liu, Xiaoyu Zhang, Qingyan Yuan, Mingyao Liu, Deshan Li, Guiping Ren. Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway. Endocrine. 2015 Nov 25
(Impact Factor: 3.878)

教材：
1、基因工程制药，主编，高等学校制药工程专业规划教材，化学工业出版社，2010


 近五年授权的专利等情况
1. 可溶性表达NotⅠ的工程菌及其构建方法和应用
发明人：任桂萍，李德山，张巧，叶贤龙

2. 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途
发明人：李德山，任桂萍，高华山，王文飞，刘铭瑶
已转化
3. 重组小分子泛素样修饰物蛋白酶及其制备方法和应用
发 明 (设计)人：李德山，傅俊华，任桂萍，王文飞，刘铭瑶
已实施许可

4. 突变的成纤维细胞生长因子及在治疗II型糖尿病中的用途
发 明 (设计)人：王文飞;吴云舟;刘铭瑶;李德山;何昆;任桂萍
已转化

5. 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用
发 明 (设计)人：李德山 叶贤龙 任桂萍 孙国鹏 刘铭瑶
已转化

6. 一种人FGF21单克隆抗体的轻链和重链可变区
发明人：刘铭瑶;郝智超;王文飞;吴云舟;任桂萍;李德山

7. 一种FGF-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用
发明人：任桂萍；朱升龙；李德山；王文飞；刘铭瑶；叶贤龙



 其他获奖及荣誉称号
龙江学者讲座教授
哈尔滨市专家顾问委员会委员